drugset / Trial / NCT00770952

Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00770952

Phase 3 Completed 91 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and glimepiride combination therapy compared to glimepiride monotherapy in subjects with Type 2 Diabetes.

Timeline

Start
2006-12
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 4 mg Oral
Subject Glimepiride Small molecule 6 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral